approval
saveSKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
community read0 votes
Sponsor: ABBVIE INC. Form: INJECTABLE. Route: INTRAVENOUS
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMar 18, 2026 · 200d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMar 18, 2026 · 200d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMar 6, 2026 · 212d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMar 6, 2026 · 212d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalSep 3, 2025 · 396d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMay 7, 2025 · 515d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMay 7, 2025 · 515d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalJun 18, 2024 · 838d ago
same company · ±60 days · 6
- approvalrisankizumab: SKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalSep 3, 2025
- approvalupadacitinib tartrate ER: RINVOQ (UPADACITINIB) — FDA approvalAug 12, 2025
- approvalatogepant: QULIPTA (ATOGEPANT) — FDA approvalSep 30, 2025
- approvalESCITALOPRAM OXALATE — FDA approvalOct 9, 2025
- approvalupadacitinib tartrate ER: RINVOQ (UPADACITINIB) — FDA approvalOct 10, 2025
- approvalupadacitinib: RINVOQ LQ (UPADACITINIB) — FDA approvalOct 10, 2025
comments(0)
5-min edit window · permanent after that